A sponsor-focused overview of clinical trials in Romania; including EU regulatory harmonization, the 30-day silent approval pathway, broad patient access, academic medical strength, and rapid market growth.
Romania is one of the most promising emerging markets for clinical trials in Europe. With 19 million people, EU regulatory alignment, a large academic medical network, and accelerated approval pathways, Romania offers sponsors access to diverse patient populations and expanding site capacity at competitive cost.
Clinical trials are regulated by the National Agency for Medicines and Medical Devices of Romania (ANMDMR) under the EU CTR framework, with a landmark 30-day silent approval law passed in July 2022 that dramatically accelerated the country's regulatory environment. Romania's clinical research market was estimated at €72 million in 2019 and is projected to triple to over €210 million by 2026; reflecting the rapid growth trajectory driven by regulatory reform and rising international sponsor interest.
Romania's 19 million people are predominantly ethnically Romanian (~89%), with Hungarian (~6%), Roma (~3%), and smaller Ukrainian, German, and other minority communities. The country's population is relatively young compared to Western Europe and carries a significant burden of non-communicable diseases; cardiovascular disease, cancer, diabetes, and chronic respiratory conditions; driven by lifestyle factors and historically limited access to specialist care. This creates large pools of treatment-naïve patients, particularly for conditions where Western European patients have already been extensively enrolled in prior studies.
Romania also has 17 medical universities and 39 university clinics; a remarkably rich academic medical infrastructure for a country of its size; producing a deep pool of qualified, English-speaking clinical investigators trained in EU GCP standards. Many Romanian physicians have completed residency or fellowship training in Western Europe or North America, giving them international research experience and familiarity with global sponsor expectations.
Strategic position: Romania's EU membership means all regulatory submissions, ethics approvals, and trial data are handled under the same legal framework as France, Germany, or Spain; with full CTIS integration. For sponsors running EU-wide trials, adding Romania requires minimal additional regulatory effort while providing access to a large, engaged, treatment-naïve patient pool at significantly lower cost.
Romania's core proposition is value: EU-equivalent regulatory standards at Eastern European cost levels, with a growing investigator pool that is actively seeking trial partnerships. The 2022 silent approval law addressed the historic bottleneck of slow ANMDMR decisions, and the National Strategic Plan for the Development of Clinical Trials; coordinated by ANMDMR and the Health Innovation Hub; signals government commitment to making Romania a regional clinical research leader. Iași's medical imaging cluster is recognized as the EU's leading cluster of its kind.
30-day silent approval law (2022); full EU CTR/CTIS integration; parallel ANMDMR and CNBMDM review; one harmonized EU-wide submission via CTIS includes Romania at no extra regulatory cost.
Significantly lower per-patient and trial operating costs than Western Europe; competitive investigator fees; lower site overhead; favorable RON/EUR exchange dynamic; projected market growth to €210M by 2026 attracting further CRO investment.
19M people with large treatment-naïve pools in cardiovascular, oncology, and metabolic disease; high patient motivation and low dropout rates; universal Social Health Insurance (SHI) ensuring structured patient access; eager investigator community.
17 medical universities; 39 university clinics; EU's leading medical imaging cluster in Iași; 3,035 trials on CT.gov; fully EU-harmonized GCP standards; growing international CRO presence (Arensia, Cromos, ICON, IQVIA).
Oncology, cardiovascular disease, and neurology are Romania's dominant therapeutic areas, reflecting both the country's disease burden and its investigator strengths. Romania has a significant burden of colorectal cancer, breast cancer, and lung cancer; all high-prevalence diseases with large pools of newly diagnosed, treatment-naïve patients. Cardiovascular disease is the leading cause of mortality, creating strong Phase III trial opportunities. Endocrinology (including diabetes) and infectious disease also feature prominently. The National Strategic Plan specifically targets expansion into rare diseases and advanced therapies.
Bucharest dominates Romania's trial activity, home to the country's largest hospital complexes and multiple medical university affiliates. Cluj-Napoca is a rapidly growing secondary hub; often called Romania's innovation capital; with an active university hospital network and a growing tech-healthcare ecosystem. Iași (EU's medical imaging leader), Timișoara, and Craiova provide important regional coverage.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Fundeni Clinical Institute | Bucharest | Romania's premier academic hospital; hematology, oncology, gastroenterology, and organ transplantation specialty; "Carol Davila" University affiliate; Phase I–IV across multiple therapeutic areas; major commercial Phase II–III portfolio; EU-recognized center of excellence |
| 02 | Arensia Exploratory Medicine; Bucharest | Bucharest | Dedicated Phase I exploratory medicine unit; oncology and non-oncology early-phase specialist; EU GCP compliant; 30-day silent approval pioneer; international sponsor CRO; connects European and US biotech to Romanian early-phase capability |
| 03 | Colentina Clinical Hospital | Bucharest | "Carol Davila" University affiliate; dermatology, rheumatology, and neurology specialty; active Phase II–IV commercial portfolio; strong international sponsor relationships; cardiovascular and metabolic disease research |
| 04 | Cluj-Napoca University Clinical Hospital | Cluj-Napoca | "Iuliu Hațieganu" Medical University affiliate; Romania's largest regional academic hospital outside Bucharest; oncology, cardiovascular, neurology, and endocrinology trials; growing Phase II–III portfolio; Cluj-Napoca tech ecosystem proximity |
| 05 | Oncology Institute "Prof. Dr. Ion Chiricuță" (IOCN) | Cluj-Napoca | Romania's second major cancer institute; "Iuliu Hațieganu" University affiliate; Phase II–III oncology trials; breast, lung, colorectal, and hematologic malignancy focus; active investigator-initiated and commercial portfolio |
| 06 | Iași County Emergency Clinical Hospital (St. Spiridon) | Iași | "Grigore T. Popa" University affiliate; Northeast Romania anchor; cardiovascular, neurology, and oncology trials; EU's leading medical imaging cluster proximity; Phase II–IV commercial portfolio |
| 07 | Institute of Cardiovascular Diseases "Prof. Dr. C.C. Iliescu" | Bucharest | Romania's leading cardiovascular research institute; Phase II–III cardiovascular outcome and device trials; interventional cardiology specialty; EU CTR-compliant research infrastructure; large cardiovascular patient catchment in Bucharest |
| 08 | National Institute of Endocrinology "C.I. Parhon" | Bucharest | Romania's dedicated endocrinology research institute; diabetes, thyroid, adrenal, and metabolic disease trials; Phase II–IV; large treatment-naïve diabetic patient pool; "Carol Davila" University affiliate |
| 09 | Elias University Emergency Hospital | Bucharest | "Carol Davila" University affiliate; oncology, rheumatology, and internal medicine trials; active Phase II–IV commercial portfolio; central Bucharest location with excellent patient access |
| 10 | Timișoara Municipal Emergency Clinical Hospital | Timișoara | "Victor Babeș" University affiliate; Western Romania anchor; oncology, cardiovascular, and neurology trials; access to Banat region's patient populations; EU capital of culture 2023; growing international profile |
| 11 | Craiova Emergency Clinical County Hospital | Craiova | University of Medicine Craiova affiliate; Southern Romania anchor; oncology, cardiovascular, and infectious disease trials; access to Oltenia region's patient population; growing Phase II–III commercial portfolio |
| 12 | National Institute of Infectious Diseases "Prof. Dr. Matei Balș" | Bucharest | Romania's leading infectious disease institution; HIV, hepatitis, and emerging pathogen trials; COVID-19 trial experience; Phase II–IV portfolio; EU infectious disease network participation |
| 13 | Clinical Hospital of Psychiatry "Prof. Dr. Alex. Obregia" | Bucharest | Romania's leading psychiatric research hospital; CNS and neuropsychiatric trials; Phase II–III commercial portfolio; large inpatient and outpatient psychiatric patient catchment; growing international pharma interest in Romanian CNS data |
| 14 | Brașov County Emergency Clinical Hospital | Brașov | Transylvania regional anchor; cardiovascular, oncology, and metabolic disease trials; access to central Romania's patient population; growing Phase II–III commercial portfolio with EU CTR submissions |
| 15 | Military Emergency University Hospital "Dr. Carol Davila" | Bucharest | "Carol Davila" University affiliate; oncology, cardiovascular, and orthopedics trials; Bucharest metropolitan patient access; EU GCP compliant; growing commercial Phase II–III portfolio |
Romania's premier academic hospital; hematology, oncology, gastroenterology, and organ transplantation specialty; "Carol Davila" University affiliate; Phase I–IV across multiple therapeutic areas; major commercial Phase II–III portfolio; EU-recognized center of excellence
Dedicated Phase I exploratory medicine unit; oncology and non-oncology early-phase specialist; EU GCP compliant; 30-day silent approval pioneer; international sponsor CRO; connects European and US biotech to Romanian early-phase capability
"Carol Davila" University affiliate; dermatology, rheumatology, and neurology specialty; active Phase II–IV commercial portfolio; strong international sponsor relationships; cardiovascular and metabolic disease research
"Iuliu Hațieganu" Medical University affiliate; Romania's largest regional academic hospital outside Bucharest; oncology, cardiovascular, neurology, and endocrinology trials; growing Phase II–III portfolio; Cluj-Napoca tech ecosystem proximity
Romania's second major cancer institute; "Iuliu Hațieganu" University affiliate; Phase II–III oncology trials; breast, lung, colorectal, and hematologic malignancy focus; active investigator-initiated and commercial portfolio
"Grigore T. Popa" University affiliate; Northeast Romania anchor; cardiovascular, neurology, and oncology trials; EU's leading medical imaging cluster proximity; Phase II–IV commercial portfolio
Romania's leading cardiovascular research institute; Phase II–III cardiovascular outcome and device trials; interventional cardiology specialty; EU CTR-compliant research infrastructure; large cardiovascular patient catchment in Bucharest
Romania's dedicated endocrinology research institute; diabetes, thyroid, adrenal, and metabolic disease trials; Phase II–IV; large treatment-naïve diabetic patient pool; "Carol Davila" University affiliate
"Carol Davila" University affiliate; oncology, rheumatology, and internal medicine trials; active Phase II–IV commercial portfolio; central Bucharest location with excellent patient access
"Victor Babeș" University affiliate; Western Romania anchor; oncology, cardiovascular, and neurology trials; access to Banat region's patient populations; EU capital of culture 2023; growing international profile
University of Medicine Craiova affiliate; Southern Romania anchor; oncology, cardiovascular, and infectious disease trials; access to Oltenia region's patient population; growing Phase II–III commercial portfolio
Romania's leading infectious disease institution; HIV, hepatitis, and emerging pathogen trials; COVID-19 trial experience; Phase II–IV portfolio; EU infectious disease network participation
Romania's leading psychiatric research hospital; CNS and neuropsychiatric trials; Phase II–III commercial portfolio; large inpatient and outpatient psychiatric patient catchment; growing international pharma interest in Romanian CNS data
Transylvania regional anchor; cardiovascular, oncology, and metabolic disease trials; access to central Romania's patient population; growing Phase II–III commercial portfolio with EU CTR submissions
"Carol Davila" University affiliate; oncology, cardiovascular, and orthopedics trials; Bucharest metropolitan patient access; EU GCP compliant; growing commercial Phase II–III portfolio
These are the primary regulatory, academic, and industry bodies shaping Romania's clinical research ecosystem.
National competent authority; 30-day silent approval law (2022); full EU CTR/CTIS integration; one of the coordinating bodies of Romania's National Strategic Plan for Clinical Trials; active engagement with EUCROF and EMA
Developing Romania's National Strategic Plan for Clinical Trials; assessing 2023 baseline capacity; national stakeholder alignment; goal to position Romania as a key EU regional clinical trial player
Ethics review body for clinical trials; Part I (EU CTR scientific review) and Part II (national ethics review); operates in parallel with ANMDMR for coordinated approval within EU CTR timelines
Romania's largest and most prestigious medical university; affiliated with Fundeni, Colentina, and other major Bucharest hospitals; drives investigator pipeline for national and international trials
Western Romania's leading medical university; affiliated with Cluj University Hospital and IOCN; growing Phase I–III investigator base; Cluj-Napoca's tech and healthcare convergence ecosystem
Northeast Romania's anchor medical university; EU medical imaging cluster in Iași; affiliated with St. Spiridon hospital; growing Phase II–IV research portfolio
Phase I and early-phase specialist with Bucharest operations; pioneered Romania's 30-day silent approval pathway; oncology and non-oncology; European CRO with deep Romanian regulatory expertise
Ukraine-headquartered CRO with major Romanian operations; 95% enrollment target achievement rate; Phase I–IV; full regulatory and contracting management; multiple therapeutic areas
Global CRO with Bucharest office; Phase I–IV management; ANMDMR/CTIS regulatory expertise; site network across all major Romanian hospitals; data management and analytics
Full-spectrum clinical trials CRO with Romanian operations; Phase I–IV; EU CTR/CTIS specialist; qualified investigators and experienced site management teams across Bucharest, Cluj, and Iași
For sponsors evaluating clinical trials in Romania, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Romania is Eastern Europe's most underutilized clinical research market; and the gap between its potential and its current trial volume is exactly where the opportunity lies. With 19 million people, a 30-day silent approval law, full EU CTR integration, 17 medical universities, 39 university clinics, a market projected to triple by 2026, and costs well below Western Europe, Romania is structurally well-positioned for significant growth. The government has committed to a National Strategic Plan. International CROs are actively building infrastructure. The EU medical imaging center of excellence is in Iași. The only question is timing; and for sponsors willing to move early, Romania offers the combination of Western regulatory standards, Eastern European value, and eager investigator communities that characterized Hungary and the Czech Republic a decade ago.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.